NVCR News and Press, NovoCure Limited From 01/05/23

The stock market remained volatile on Thursday, with investors reacting negatively to signs that the economy might be too strong for the Federal Reserve to slow the pace of its interest rate increases. After having been slightly higher earlier in the morning, the Nasdaq Composite (NASDAQIND...

U.S.-based health equipment developer NovoCure Limited ( NASDAQ: NVCR ) and Chinese biotech Zai Lab Limited ( NASDAQ: ZLAB ) announced Thursday that their pivotal Phase 3 trial for Tumor Treating Fields (TTFields) met the primary endpoint in non-small cell lung cancer (NSCLC). ...

The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival The full LUNAR data will be presented at a future medical congress SHANGHAI and CAMBRIDGE, Mass. and ROOT, Switzerland, Jan. 05, 2023 (GLOB...

The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival The full LUNAR data will be presented at a future medical congress Novocure (NASDAQ: NVCR) today announced the LUNAR study met its primar...

Summary ARK Invest does great deep-dive research. Utilize their insights along with market timing considerations to generate alpha. The performance of ARKG is dictated mostly by interest rate decisions in the current environment. But underneath the macro layer, there are many promising ...

Novocure (NASDAQ: NVCR) announced today it will participate in the 41 st Annual J. P. Morgan Healthcare Conference on January 10-11, 2023. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 7:30 a.m. PST on January 1...

The jolly fellow with a white beard and a red-and-white suit doesn't just bring presents to children. He sometimes delivers gifts to investors, too. Years ago, investors observed that a phenomenon dubbed the Santa Claus rally often occurred during the year-end holidays. In many cases, stocks ...

Stock prices have been all over the place in 2022, making it a rather scary year for investors . The S&P 500 , which closed 2021 with 27% gains, is down 22% so far this year, as of this writing. It'll be an absolute stunner if the index can end 2022 in the green. Yet, December bri...

Optune is the first treatment for glioblastoma approved in Canada in over 12 years Novocure is actively working to secure reimbursement of Optune to make the therapy accessible for glioblastoma patients Novocure (NASDAQ: NVCR) today announced that Health Canada has a...

Many companies like to claim that they have revolutionary, game-changing products. Few live up to the hype. Novocure (NASDAQ: NVCR) could be an exception. Its tumor-treating fields (TTFields) therapy uses electrical signals to disrupt the division of tumor cells. But just be...